The strength of small: Improved targeting of Insulin-like Growth Factor-1 Receptor (IGF-1R) with F(ab′)2-R1507 fragments in Ewing sarcomas

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2851-2858

  Fleuren, Emmy D G ^a   Versleijen Jonkers, Yvonne M H ^a   Heskamp, Sandra ^a   Roeffen, Melissa H S ^a   Bouwman, Wilbert H ^a   Molkenboer Kuenen, Janneke D M ^a   Van Laarhoven, Hanneke W M ^a,b   Oyen, Wim J G ^a   Boerman, Otto C ^a   Van Der Graaf, Winette T A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Ewing sarcoma; F(ab')2; IGF 1R; Immuno SPECT; R1507

Indexed keywords

ANTINEOPLASTIC AGENT; F(AB')2 R1507 FRAGMENT IN 111; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F(AB')2 R1507 FRAGMENT; R 1507; R 1507 IN 111; RADIOISOTOPE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT;

EWING SARCOMA; F(AB′)(2); IGF-1R; IMMUNO-SPECT; R1507;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, IGF TYPE 1; SARCOMA, EWING; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881090688     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.009     Document Type: Article

References (37)

1. N.J. Balamuth, and R.B. Womer Ewing's sarcoma Lancet Oncol 11 2010 184 192
2. P.J. Grohar, and L.J. Helman Prospects and challenges for the development of new therapies for Ewing sarcoma Pharmacol Ther 137 2013 216 224
3. E. Foulstone, S. Prince, and O. Zaccheo Insulin-like growth factor ligands, receptors, and binding proteins in cancer J Pathol 205 2005 145 153
4. M. Wachtel, and B.W. Schafer Targets for cancer therapy in childhood sarcomas Cancer Treat Rev 36 2010 318 327
5. R.G. Maki Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer J Clin Oncol 28 2010 4985 4995
6. E.D. Fleuren, Y.M. Versleijen-Jonkers, and A.C. van de Luijtgaarden Predicting IGF-1R therapy response in bone sarcomas: immuno-spect imaging with radiolabeled R1507 Clin Cancer Res 17 2011 7693 7703
7. E.A. Kolb, R. Gorlick, and P.J. Houghton Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program Pediatr Blood Cancer 50 2008 1190 1197
8. R.T. Kurmasheva, L. Dudkin, C. Billups, L.V. Debelenko, C.L. Morton, and P.J. Houghton The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma Cancer Res 69 2009 7662 7671
9. S. Malempati, B. Weigel, and A.M. Ingle Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group J Clin Oncol 30 2012 256 262
10. D. Olmos, S. Postel-Vinay, and L.R. Molife Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study Lancet Oncol 11 2010 129 135
11. A.S. Pappo, S.R. Patel, and J. Crowley R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study J Clin Oncol 29 2011 4541 4547
12. W.D. Tap, G. Demetri, and P. Barnette Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors J Clin Oncol 30 2012 1849 1856
13. K. Scotlandi, M.C. Manara, and M. Serra Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival Eur J Cancer 47 2011 1258 1266
14. A.C. van de Luijtgaarden, Y.M. Versleijen-Jonkers, M.H. Roeffen, H.W. Schreuder, U.E. Flucke, and W.T. van der Graaf Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients Target Oncol 2013 [epub aheah of print]
15. I. Asmane, E. Watkin, and L. Alberti Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas Eur J Cancer 48 2012 3027 3035
16. V. Subbiah, A. Naing, and R.E. Brown Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures PLoS One 6 2011 e18424
17. S. Heskamp, H.W.M. van Laarhoven, and J.D.M. Molkenboer-Kuenen ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model J Nucl Med 51 2010 1565 1572
18. R.K. Jain Physiological barriers to delivery of monoclonal-antibodies and other macromolecules in tumors Cancer Res 50 1990 S814 S819
19. A. Brouwers, P. Mulders, and E. Oosterwijk Pharmacokinetics and tumor targeting of I-131-labeled F(ab′)(2) fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies Cancer Biother Radiopharm 19 2004 466 477
20. K.J. Wong, K.E. Baidoo, T.K. Nayak, K. Garmestani, M.W. Brechbiel, and D.E. Milenic In vitro and in vivo pre-clinical analysis of a F(ab′)(2) fragment of panitumumab for molecular imaging and therapy of HER1 positive cancers EJNMMI Res. 1 2011 1
21. S. Heskamp, H.W. van Laarhoven, and J.D. Molkenboer-Kuenen Optimization of IGF-1R SPECT/CT imaging using (111)In-labeled F(ab′)(2) and Fab fragments of the monoclonal antibody R1507 Mol Pharm 2012 [Epub ahead of print]
22. T. Lindmo, E. Boven, F. Cuttitta, J. Fedorko, and P.A. Bunn Determination of the immunoreactive fraction of radiolabeled monoclonal-antibodies by linear extrapolation to binding at infinite antigen excess J Immunol Methods 72 1984 77 89
23. P.J. Houghton, C.L. Morton, and R. Gorlick Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program Pediatr Blood Cancer 54 2010 921 926
24. E.A. Kolb, R. Gorlick, and R. Lock Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program Pediatr Blood Cancer 56 2011 595 603
25. J.M. Carboni, M. Wittman, and Z. Yang BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR Mol Cancer Ther 8 2009 3341 3349
26. P. Sabbatini, J.L. Rowand, and A. Groy Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase Clin Cancer Res 15 2009 3058 3067
27. H.K. Bid, J. Zhan, D.A. Phelps, R.T. Kurmasheva, and P.J. Houghton Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2 Mol Cancer Ther 11 2012 649 659
28. B.A.W. Hoeben, J.H.A.M. Kaanders, and G.M. Franssen PET of hypoxia with Zr-89-labeled cG250-F(ab′)(2) in head and neck tumors J Nucl Med 51 2010 1076 1083
29. L.A. Khawli, M.M. Alauddin, P.S. Hu, and A.L. Epstein Tumor targeting properties of indium-111 labeled genetically engineered Fab′ and F(ab′)(2) constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody Cancer Biother Radiopharm 18 2003 931 940
30. H. Akizawa, T. Uehara, and Y. Arano Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins Adv Drug Deliv Rev 60 2008 1319 1328
31. C.P. Carden, S. Frentzas, and M. Langham Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors J Clin Oncol 27 Suppl. 2009 Abstr. 3544
32. E.S. Kim, I. Puzanov, and E. Buck Activity of the IGF1-R/IR inhibitor OSI-906 in non-small cell lung cancer (NSCLC): pre-clinical and early clinical experience J Thorac Oncol 5 2010 S543
33. M.J. Mulvihill, A. Cooke, and M. Rosenfeld-Franklin Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor Future Med Chem 1 2009 1153 1171
34. T. Aleksic, M.M. Chitnis, and O.V. Perestenko Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells Cancer Res 70 2010 6412 6419
35. S.L. Li, S.J. Liang, N. Guo, A.M. Wu, and Y. Fujita-Yamaguchi Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth Cancer Immunol Immunother 49 2000 243 252
36. D. Sachdev, S.L. Li, J.S. Hartell, Y. Fujita-Yamaguchi, J.S. Miller, and D. Yee A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I Cancer Res 63 2003 627 635
37. V. Tolmachev, J. Malmberg, and C. Hofstrom Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule In-111-DOTA-Z(IGF1R:4551) J Nucl Med 53 2012 90 97